Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 125

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 125
---
 potentially harmful polar organic solvents and are ready
for use (GelrinC). The family of patent applications derived from WO 2017/103924 are granted in China, CN 108472413, India, IN 457479
and Israel, IL 259891 and includes pending patent application Nos. US 2022/0105240, EP 3389736, CA 3006695, and JP 2023-180906, which
are detailed in the table below. The pending patent applications are still in different stages of examination and may not mature into
actual granted patents. Thus, there is a risk that if any one or more family members are not granted, the improved compositions will
not be patent protected in their respective territory.

GelrinV and GelrinP

A second “pipeline
product” of the Company is designated as GelrinV and it is a product using a conjugate of fibrinogen with a polaxamer (Pluronic)
for the treatment of osteoarthritis. The product exhibits thermo-reversible gelation, is water-immiscible and can be delivered using
a minimally invasive application. It is designed to a form of a paste in the cavity upon UVA irradiation.

This product is more viscous
and better suited for the intended purpose of providing relief from chronic conditions including osteoarthritis. This second potential
product is described by the third family of patents derived from WO 2011/07399, which was filed December 16, 2010. Patents from this
family are nominally due to expire in December 2030 and include patents Nos. US 8,846,020, EP 2513294, CN 102762715 and IL 220343, which
are detailed in the table below.

GelrinP derived from WO 2014/207749
filed June 24, 2014 claims an injectable curable paste that can be shaped to fill defects requiring treatment. The family of patent applications
derived from WO 2014/207749 includes patents Nos. US 10,434,215, EP 3013377 and CN 105407933, which are detailed in the table below.

A patent derived from WO
2008/126092, patent No. US 9,624,259, that was filed April 16, 2008, claims conjugates of the serum protein albumin with PEG.